- Novo Nordisk A/S (NYSE:NVO) has announced topline results from Phase 3a ONWARDS 2 trial, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs. insulin degludec.
- The study included 526 people with type 2 diabetes switching from daily insulin.
- The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec compared to insulin degludec.
- From an overall baseline HbA1c of 8.13%, once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of 0.93% compared to 0.71% for insulin degludec (estimated treatment difference: -0.22%).
- No statistical difference in estimated hypoglycemia rates and no severe hypoglycemia events were observed for people treated with insulin icodec.
- The rates of severe or clinically significant hypoglycemia (blood glucose below 3 mmol/L) were 0.73 events per patient-year exposed to once-weekly insulin icodec and 0.27 events per patient-year exposed to insulin degludec.
- In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile.
- The ONWARD program has another five trials undergoing testing once-weekly insulin icodec.
- Price Action: NVO shares are down 0.74% at $110.74 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Novo Nordisk's Once-Weekly Insulin Icodec Shows Favorable Reduction In HbA1c In Type 2 Diabetes
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks